<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EC1D7232-9B00-44B3-BBAA-ACB3381663DD"><gtr:id>EC1D7232-9B00-44B3-BBAA-ACB3381663DD</gtr:id><gtr:name>Blueberry Therapeutics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/47CC4050-87A9-4965-B949-35C9C52402DA"><gtr:id>47CC4050-87A9-4965-B949-35C9C52402DA</gtr:id><gtr:name>Pharmidex</gtr:name><gtr:address><gtr:line1>Pharmidex</gtr:line1><gtr:line2>72 New Bond Street</gtr:line2><gtr:line3>Mayfair</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W15 1RR</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4018EB61-685A-4231-B8F0-837CCA154C5F"><gtr:id>4018EB61-685A-4231-B8F0-837CCA154C5F</gtr:id><gtr:name>M.C.I Animal Health</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2E0EC069-6E74-4ED4-A5F1-1ABD4EDB1626"><gtr:id>2E0EC069-6E74-4ED4-A5F1-1ABD4EDB1626</gtr:id><gtr:name>Godrej Group</gtr:name><gtr:address><gtr:line1>Eastern Express Highway</gtr:line1><gtr:line2>Vikhroli</gtr:line2><gtr:postCode>400079</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6C168531-28B2-40BE-A7A6-842A96FD01AD"><gtr:id>6C168531-28B2-40BE-A7A6-842A96FD01AD</gtr:id><gtr:name>Redx Pharma Plc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EE905F03-3AE9-49D0-8400-F19A2869BD60"><gtr:id>EE905F03-3AE9-49D0-8400-F19A2869BD60</gtr:id><gtr:name>Vaccitech Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CBEBA2E5-F982-48DE-B88E-D505FB6F1492"><gtr:id>CBEBA2E5-F982-48DE-B88E-D505FB6F1492</gtr:id><gtr:name>The Clatterbridge Cancer Centre NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/36B63BC7-A510-403B-9B57-65C5DE5CB8CE"><gtr:id>36B63BC7-A510-403B-9B57-65C5DE5CB8CE</gtr:id><gtr:name>Smith College</gtr:name><gtr:address><gtr:line1>Smith College</gtr:line1><gtr:postCode>MA 01063</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A19DEFFA-FECA-4E87-B8C6-A2BC9F43550F"><gtr:id>A19DEFFA-FECA-4E87-B8C6-A2BC9F43550F</gtr:id><gtr:name>Epistem</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/25F3D5C3-4E07-4D2F-B1CA-4211FA3156B0"><gtr:id>25F3D5C3-4E07-4D2F-B1CA-4211FA3156B0</gtr:id><gtr:name>Salvensis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D"><gtr:id>DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D</gtr:id><gtr:name>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A9BE6F2A-7F69-4499-8DCC-04808C493698"><gtr:id>A9BE6F2A-7F69-4499-8DCC-04808C493698</gtr:id><gtr:name>Qiagen</gtr:name><gtr:address><gtr:line1>QIAGEN GmbH</gtr:line1><gtr:line2>QIAGEN Strasse 1</gtr:line2><gtr:postCode>40724</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/19CCE457-22F6-4240-888C-EA086D625526"><gtr:id>19CCE457-22F6-4240-888C-EA086D625526</gtr:id><gtr:name>Kalinga Institute of Industrial Technology (KIIT) University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FAA77269-CB2A-42CE-81EF-0E594636D7A2"><gtr:id>FAA77269-CB2A-42CE-81EF-0E594636D7A2</gtr:id><gtr:name>Avacta Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D575530D-7807-42DC-9AFD-AE0C3F87AF96"><gtr:id>D575530D-7807-42DC-9AFD-AE0C3F87AF96</gtr:id><gtr:name>Xeroshield</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/583BF071-35F9-46B0-816A-C9B20AFC53CC"><gtr:id>583BF071-35F9-46B0-816A-C9B20AFC53CC</gtr:id><gtr:name>Alder Hey Children's NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A22AE6ED-CA68-44B7-A675-49AB8B3859E0"><gtr:id>A22AE6ED-CA68-44B7-A675-49AB8B3859E0</gtr:id><gtr:name>Vellore Institute of Technology (VIT) University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/941C2E74-C576-49DA-9987-CE40EF8A611D"><gtr:id>941C2E74-C576-49DA-9987-CE40EF8A611D</gtr:id><gtr:name>Pfizer</gtr:name><gtr:address><gtr:line1>235 East 42nd Street</gtr:line1><gtr:postCode>10017</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5362E4F8-F47B-4B62-B8EE-FEEDB4BD2C94"><gtr:id>5362E4F8-F47B-4B62-B8EE-FEEDB4BD2C94</gtr:id><gtr:name>Kirkstall Ltd</gtr:name><gtr:address><gtr:line1>Unit 3 Aspen Court</gtr:line1><gtr:line2>Aspen Way</gtr:line2><gtr:line3>Centurion Business Park</gtr:line3><gtr:postCode>S60 1FB</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F4E9964B-E1BB-42CB-B2B9-998086AE0EF5"><gtr:id>F4E9964B-E1BB-42CB-B2B9-998086AE0EF5</gtr:id><gtr:name>BioGene</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E004D198-2D95-4A20-BBA5-B10F5B0E1753"><gtr:id>E004D198-2D95-4A20-BBA5-B10F5B0E1753</gtr:id><gtr:name>Instituto Butantan</gtr:name><gtr:address><gtr:line1>Vital Brazil Avenue, 1500</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC1D7232-9B00-44B3-BBAA-ACB3381663DD"><gtr:id>EC1D7232-9B00-44B3-BBAA-ACB3381663DD</gtr:id><gtr:name>Blueberry Therapeutics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/47CC4050-87A9-4965-B949-35C9C52402DA"><gtr:id>47CC4050-87A9-4965-B949-35C9C52402DA</gtr:id><gtr:name>Pharmidex</gtr:name><gtr:address><gtr:line1>Pharmidex</gtr:line1><gtr:line2>72 New Bond Street</gtr:line2><gtr:line3>Mayfair</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W15 1RR</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4018EB61-685A-4231-B8F0-837CCA154C5F"><gtr:id>4018EB61-685A-4231-B8F0-837CCA154C5F</gtr:id><gtr:name>M.C.I Animal Health</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2E0EC069-6E74-4ED4-A5F1-1ABD4EDB1626"><gtr:id>2E0EC069-6E74-4ED4-A5F1-1ABD4EDB1626</gtr:id><gtr:name>Godrej Group</gtr:name><gtr:address><gtr:line1>Eastern Express Highway</gtr:line1><gtr:line2>Vikhroli</gtr:line2><gtr:postCode>400079</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6C168531-28B2-40BE-A7A6-842A96FD01AD"><gtr:id>6C168531-28B2-40BE-A7A6-842A96FD01AD</gtr:id><gtr:name>Redx Pharma Plc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE905F03-3AE9-49D0-8400-F19A2869BD60"><gtr:id>EE905F03-3AE9-49D0-8400-F19A2869BD60</gtr:id><gtr:name>Vaccitech Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CBEBA2E5-F982-48DE-B88E-D505FB6F1492"><gtr:id>CBEBA2E5-F982-48DE-B88E-D505FB6F1492</gtr:id><gtr:name>The Clatterbridge Cancer Centre NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/36B63BC7-A510-403B-9B57-65C5DE5CB8CE"><gtr:id>36B63BC7-A510-403B-9B57-65C5DE5CB8CE</gtr:id><gtr:name>Smith College</gtr:name><gtr:address><gtr:line1>Smith College</gtr:line1><gtr:postCode>MA 01063</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A19DEFFA-FECA-4E87-B8C6-A2BC9F43550F"><gtr:id>A19DEFFA-FECA-4E87-B8C6-A2BC9F43550F</gtr:id><gtr:name>Epistem</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/25F3D5C3-4E07-4D2F-B1CA-4211FA3156B0"><gtr:id>25F3D5C3-4E07-4D2F-B1CA-4211FA3156B0</gtr:id><gtr:name>Salvensis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D"><gtr:id>DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D</gtr:id><gtr:name>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A9BE6F2A-7F69-4499-8DCC-04808C493698"><gtr:id>A9BE6F2A-7F69-4499-8DCC-04808C493698</gtr:id><gtr:name>Qiagen</gtr:name><gtr:address><gtr:line1>QIAGEN GmbH</gtr:line1><gtr:line2>QIAGEN Strasse 1</gtr:line2><gtr:postCode>40724</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/19CCE457-22F6-4240-888C-EA086D625526"><gtr:id>19CCE457-22F6-4240-888C-EA086D625526</gtr:id><gtr:name>Kalinga Institute of Industrial Technology (KIIT) University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FAA77269-CB2A-42CE-81EF-0E594636D7A2"><gtr:id>FAA77269-CB2A-42CE-81EF-0E594636D7A2</gtr:id><gtr:name>Avacta Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D575530D-7807-42DC-9AFD-AE0C3F87AF96"><gtr:id>D575530D-7807-42DC-9AFD-AE0C3F87AF96</gtr:id><gtr:name>Xeroshield</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/583BF071-35F9-46B0-816A-C9B20AFC53CC"><gtr:id>583BF071-35F9-46B0-816A-C9B20AFC53CC</gtr:id><gtr:name>Alder Hey Children's NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A22AE6ED-CA68-44B7-A675-49AB8B3859E0"><gtr:id>A22AE6ED-CA68-44B7-A675-49AB8B3859E0</gtr:id><gtr:name>Vellore Institute of Technology (VIT) University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/941C2E74-C576-49DA-9987-CE40EF8A611D"><gtr:id>941C2E74-C576-49DA-9987-CE40EF8A611D</gtr:id><gtr:name>Pfizer</gtr:name><gtr:address><gtr:line1>235 East 42nd Street</gtr:line1><gtr:postCode>10017</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5362E4F8-F47B-4B62-B8EE-FEEDB4BD2C94"><gtr:id>5362E4F8-F47B-4B62-B8EE-FEEDB4BD2C94</gtr:id><gtr:name>Kirkstall Ltd</gtr:name><gtr:address><gtr:line1>Unit 3 Aspen Court</gtr:line1><gtr:line2>Aspen Way</gtr:line2><gtr:line3>Centurion Business Park</gtr:line3><gtr:postCode>S60 1FB</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F4E9964B-E1BB-42CB-B2B9-998086AE0EF5"><gtr:id>F4E9964B-E1BB-42CB-B2B9-998086AE0EF5</gtr:id><gtr:name>BioGene</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E004D198-2D95-4A20-BBA5-B10F5B0E1753"><gtr:id>E004D198-2D95-4A20-BBA5-B10F5B0E1753</gtr:id><gtr:name>Instituto Butantan</gtr:name><gtr:address><gtr:line1>Vital Brazil Avenue, 1500</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/35C0CE50-61C8-4951-A6BD-C121ABC82F8E"><gtr:id>35C0CE50-61C8-4951-A6BD-C121ABC82F8E</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Ward</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_14111"><gtr:id>87756095-A320-47DD-B1D2-397128E3139A</gtr:id><gtr:title>Tropical Infectious Disease Consortium: Sustaining, Expanding and Accelerating Product Development</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_14111</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2016-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>500000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pharmidex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PK/PD studies ( Drug accumulation)</gtr:description><gtr:id>C52BE72D-C5ED-4FCA-B6B9-AD120C4B6201</gtr:id><gtr:impact>Drug accumulation studies have been completed for two standard drugs. A significant difference is seen in the concentration of drug within the cells between the static and the flow systems.</gtr:impact><gtr:outcomeId>58b6e91daa1db4.86399329-1</gtr:outcomeId><gtr:partnerContribution>Pharmidex took the samples and analysed them to find exact drug concentrations in the nanomolar range.</gtr:partnerContribution><gtr:piContribution>Drug accumulation studies were conducted using a media perfusion system. LSHTM used the media perfusion system and conducted a drug assay that was then placed under flow conditions to compare to a static system. LSHTM completed the assay and extracted drug samples from the cells after different times.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Alder Hey Children's NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Alder Hey Collaboration</gtr:description><gtr:id>3EB2BFA6-482E-472F-90ED-16882F124B51</gtr:id><gtr:impact>We have currently recruited all 10 volunteers and 7/10 patients with sepsis. We plan to use this information to generate peer reviewed papers</gtr:impact><gtr:outcomeId>58b940cf992109.81018841-1</gtr:outcomeId><gtr:partnerContribution>Alder Hey wrote the ethical amendment and child information / parental consent forms for the study. Subsequently Alder Hey have screened, consented and took blod form children before transporting it to LSTM for analysis.</gtr:partnerContribution><gtr:piContribution>We have processed blood samples taken from children admitted to PICU with sepsis and healthy child volunteers (blood sample taken under general anaesthetic for routine surgery). We have used our innovative assay that requires less than 2ml blood to measure neutrophil function with and without the immunostimulatory drug P4 peptide. We have processed and saved excess plasma in order to facilitate further analysis. We provided the clinical protocols and platform for the study based on our adult study used to validate the assay that we refined during the course of the award. We made available our CRN Portfolio sponsorship gained through funding of the study in order to facilitate research nurse screening and recruitment if patients.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Redx Pharma Plc</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Joint PhD Student with RedX Pharma</gtr:description><gtr:id>847BC900-DF04-4223-B166-3267230A0799</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>58221c2081c7b2.17772327-1</gtr:outcomeId><gtr:partnerContribution>This is a joint initiative between LSTM and RedX Pharma to recruit a PhD student to undertake a project at Liverpool and Alderley Park</gtr:partnerContribution><gtr:piContribution>This is a joint initiative between LSTM and RedX Pharma to recruit a PhD student to undertake a project at Liverpool and Alderley Park</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Epistem</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Godrej Group parnership</gtr:description><gtr:id>C5AFC102-D8D1-42EC-99A9-06DC286E5D09</gtr:id><gtr:impact>Early stage of project, no outputs as yet.</gtr:impact><gtr:outcomeId>56e041190fbde7.17937095-2</gtr:outcomeId><gtr:partnerContribution>Godrej are the largest producer of houshold insecticide products in India. They are providing a product market and in country facilities for field research. The UK partner, Epistem, are producing the technology for new product development and providing exprtise and materials for the project.</gtr:partnerContribution><gtr:piContribution>Developed an Indo-UK partnership to develop new diagnostics for insecticide resistance</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>MRC CiC PDE project GSK</gtr:description><gtr:id>6AB083A1-0309-44BA-BECF-D1AE252E6B93</gtr:id><gtr:impact>No outputs as yet. Data are being generated.</gtr:impact><gtr:outcomeId>56dd6d87478360.91873046-1</gtr:outcomeId><gtr:partnerContribution>Provision of compounds</gtr:partnerContribution><gtr:piContribution>Screening PDE inhibitors for activity against malaria parasites</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>M.C.I Animal Health</gtr:collaboratingOrganisation><gtr:country>Morocco, Kingdom of</gtr:country><gtr:description>Collaboration to accelerate development of vaccines against MERS-CoV</gtr:description><gtr:id>2C315B72-0A1B-4195-B061-CFFCE547B356</gtr:id><gtr:impact>A single dose of the vaccine administered intramuscularly or intranasally has been shown to provide 100% efficacy against lethal challenge in mice. Analysis of antibody titres, viral titres and histopathology are currently underway. 

Dromedary camels are now being recruited into the study at IRED, Chad and vaccine and consumable shipment will soon commence. We expect to immunise in December 2016, with results expected as from January 2017.</gtr:impact><gtr:outcomeId>57d255b360b593.98207919-2</gtr:outcomeId><gtr:partnerContribution>Vincent Munster's group at NIAID's Rocky Mountain Laboratories is testing the efficacy of the vaccine using his established transgenic mouse model.

IRED in Chad is providing camel immunisation and immunogenicity assessment. 

Vaccitech Limited, a recent University of Oxford spin-out with exclusive rights to our MERS vaccine, has provided co-funding to support camel challenge studies in Morocco.

We have sent vaccine to both these institutions, and they will send back results from mutually agreed study designs.</gtr:partnerContribution><gtr:piContribution>My research team has contributed a leading rationally designed vaccine candidate, that has already shown promise in preliminary immunogenicity studies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Salvensis</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC CiC PDE project Salvensis</gtr:description><gtr:id>D2A1E97F-B428-41CF-8B4C-9BD42888C93C</gtr:id><gtr:impact>No outputs as yet</gtr:impact><gtr:outcomeId>56dd6c3f982207.33878131-1</gtr:outcomeId><gtr:partnerContribution>Chemistry and drug discovery expertise.</gtr:partnerContribution><gtr:piContribution>We work together on screening GSK and Pfizer PDE inhibitors for activity against malaria parasites</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Godrej Group</gtr:collaboratingOrganisation><gtr:country>India, Republic of</gtr:country><gtr:description>Godrej Group parnership</gtr:description><gtr:id>2D5C95EA-B454-491D-BA4B-8DDD0F29ADAB</gtr:id><gtr:impact>Early stage of project, no outputs as yet.</gtr:impact><gtr:outcomeId>56e041190fbde7.17937095-1</gtr:outcomeId><gtr:partnerContribution>Godrej are the largest producer of houshold insecticide products in India. They are providing a product market and in country facilities for field research. The UK partner, Epistem, are producing the technology for new product development and providing exprtise and materials for the project.</gtr:partnerContribution><gtr:piContribution>Developed an Indo-UK partnership to develop new diagnostics for insecticide resistance</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kalinga Institute of Industrial Technology (KIIT) University</gtr:collaboratingOrganisation><gtr:country>India, Republic of</gtr:country><gtr:description>KIIT</gtr:description><gtr:id>211FE44A-211D-409A-9D29-399233A91BD5</gtr:id><gtr:impact>MOU and high level meetings with LSTM/Godrej/KIIT management. Multidisciplinary, Educational/ research/ industry</gtr:impact><gtr:outcomeId>57dbc0852b0fd1.68481566-1</gtr:outcomeId><gtr:partnerContribution>KIIT set-up high level meeting with LSTM Director (Hemingway) and Godrej to initiate talks on partnershp opportunities</gtr:partnerContribution><gtr:piContribution>Links made through collaboration with Godrej Industries to develop a three way Industry - UK/India academic partnership for research and training.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kirkstall Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Media perfusion assay development for Leishmaniasis</gtr:description><gtr:id>B6F25CC4-2112-4EFA-9DA1-84AD82B39AC3</gtr:id><gtr:impact>Experimentation with the media perfusion system to study the effect of media flow simulating either interstitial or blood fluid flow has been shown to reduce the overall infection caused by Leishmania parasites when compared to a static system. The higher the flow rate the lower the infection is overall after 72 hours of incubation. When testing standard drugs in this system we have found that the media perfusion alters the potency of the drugs activity. To achieve the same reduction in parasitaemia a higher concentration of drug must be used in the flow system. To enhance our understanding we have conducted drug accumulation studies that show less drug is accumulated under flow conditions.</gtr:impact><gtr:outcomeId>58b6ec6c86c581.04337840-1</gtr:outcomeId><gtr:partnerContribution>Kirkstall Ltd have provided training and support of use of the media perfusion systems they manufacture. They have helped design products to suit our experimental needs and helped us gain many useful contacts in the research area.</gtr:partnerContribution><gtr:piContribution>I have used the media perfusion system bought from Kirkstall Ltd to conduct an in-depth analysis of how the process of infection with Leishmania parasites is effected by media perfusion, used to simulate both interstitial fluid flow and blood flow. I have used the QV900 system to test four standard drugs against infected macrophages in comparison with a static control. I have conducted drug accumulation studies in the system to try and elucidate the reasons for the results we have seen previously.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Smith College</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Collaboration with Smith College</gtr:description><gtr:id>B58220CC-29FF-473F-BCFF-69C61D20387C</gtr:id><gtr:impact>Abstracts submission to ASTMH meeting in 2016. Grant submission to Bill and Melinda Gates Foundation, Grant submisison to GCRF</gtr:impact><gtr:outcomeId>57d2a60eb7f3b4.80949067-1</gtr:outcomeId><gtr:partnerContribution>Smith College is assisting with sample processing and applying new methodologies to the detection of parasite DNA in mosquito feces</gtr:partnerContribution><gtr:piContribution>We are setting up experimental infections and providing samples for Smith College to evaluate new methodoogies for detection of parasite DNA in excreta</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>BioGene</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>BioGene and QuRapID qPCR system</gtr:description><gtr:id>74D3DD21-3331-4F4C-B196-3C33B450B50F</gtr:id><gtr:impact>Publications have been added to relevant section on research fish. 
IP file in preparation for arboviral assay</gtr:impact><gtr:outcomeId>58b82c9cdfcc95.33902499-1</gtr:outcomeId><gtr:partnerContribution>Use of Visual OMP for primer/probe design. 
Test rig of the QuRapID system delivered to LSTM
PhD student Kavit Shah will start in March 2017 (student and bench fees to LSTM)
Support with development of molecular system and transfer to qurapid.</gtr:partnerContribution><gtr:piContribution>Design of primer and probes sets for the identification of anti-microbial resistance markers. Collection of bacterial isolates with AMR markers in Malawi.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Rocky Mountain Laboratories</gtr:department><gtr:description>Collaboration to accelerate development of vaccines against MERS-CoV</gtr:description><gtr:id>582DBBB2-3A90-4686-A406-2AF09A1F1763</gtr:id><gtr:impact>A single dose of the vaccine administered intramuscularly or intranasally has been shown to provide 100% efficacy against lethal challenge in mice. Analysis of antibody titres, viral titres and histopathology are currently underway. 

Dromedary camels are now being recruited into the study at IRED, Chad and vaccine and consumable shipment will soon commence. We expect to immunise in December 2016, with results expected as from January 2017.</gtr:impact><gtr:outcomeId>57d255b360b593.98207919-1</gtr:outcomeId><gtr:partnerContribution>Vincent Munster's group at NIAID's Rocky Mountain Laboratories is testing the efficacy of the vaccine using his established transgenic mouse model.

IRED in Chad is providing camel immunisation and immunogenicity assessment. 

Vaccitech Limited, a recent University of Oxford spin-out with exclusive rights to our MERS vaccine, has provided co-funding to support camel challenge studies in Morocco.

We have sent vaccine to both these institutions, and they will send back results from mutually agreed study designs.</gtr:partnerContribution><gtr:piContribution>My research team has contributed a leading rationally designed vaccine candidate, that has already shown promise in preliminary immunogenicity studies.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Cambridge Collaboration</gtr:description><gtr:id>789C0936-4D77-4D31-B275-A123A235333C</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>58b94220e5d596.50662831-1</gtr:outcomeId><gtr:partnerContribution>Dr Conway-Morris is investigating a number of neutrophil function assays as part of his work and will compare our assay against other established assays (e.g. zymosan) in an attempt to determine optimal measures.</gtr:partnerContribution><gtr:piContribution>We have provided (under NDA) the SOPs for the whole blood phagocytosis assay to Dr Andrew Conway-Morris who is an international expert in innate immune function in sepsis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Qiagen</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Co-developed of products by LSTM and Qiagen (In Vitro Diagnostics)</gtr:description><gtr:id>88932927-F892-4B9D-94A6-0535576B18C5</gtr:id><gtr:impact>Develop improved diagnostic assays for the simultaneous detection of CHK and dengue viruses. The outcomes expected are:
1. A multiplexed CHKV and DENV rt-PCR test, capable of the sensitive detection of both viruses and differentiation of DENV serotypes, which will be IVD CE certified for commercial release.
2. Performance data of the assay generated during comparative tests with &amp;quot;in house&amp;quot; rt-PCR assays and commercial ELISA tests on prospective fever cases in Ecuador and Brazil.
3. Extracted RNA from clinical specimens to enable the development of the qPCR and HDA assays at LSTM.
4. Design and initial testing of an isothermal HDA assay for CHKV.
5. Publications in international, peer reviewed, high impact factor journals.</gtr:impact><gtr:outcomeId>56ded0f8946e65.06985492-1</gtr:outcomeId><gtr:partnerContribution>Qiagen made a significant contribution to this project including a rotor gene qPCR system with 5 channel detection. This system has a transfer price of ~&amp;pound;25,000. All qPCR reaction mix, viral RNA extraction kits will be provided free of charge throughout the project, representing a significant outlay of about &amp;pound;15,000. Qiagen will also cover the costs of the CE mark request.</gtr:partnerContribution><gtr:piContribution>Assay development, initial assay validation and testing of the rt-PCR assay in surveillance laboratories, Multiplex assay optimisation, and HDA assay development.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Blueberry Therapeutics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC_CiC_CRro_nanoP</gtr:description><gtr:id>ADD5EB2F-7E05-450C-97E9-14A0FE2CABFF</gtr:id><gtr:impact>Research still in progress, but as of February 2017 is nearing completion. Stable model of macrophage infection by S. Typhi created and observed on high throughput imaging platforms. Experimental infection and treatment of cell lines now complete and data being analysed.</gtr:impact><gtr:outcomeId>5898587ec7b4b5.11674004-1</gtr:outcomeId><gtr:partnerContribution>Unchanged from previous report</gtr:partnerContribution><gtr:piContribution>Unchanged from previous report</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Blueberry Therapeutics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Novel antibiotic nano formulations</gtr:description><gtr:id>245E8DB0-1E91-4097-959A-49C686B06633</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>56ddadb0dfcfd8.01285821-1</gtr:outcomeId><gtr:partnerContribution>nano-formulation expertise and materials</gtr:partnerContribution><gtr:piContribution>Imaging and PK-PD platform to screen novel antibiotic formulations against Salmonella</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Xeroshield</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Xeroshield</gtr:description><gtr:id>F22FDCD8-2C20-48BF-8E98-5FB2BA94D57A</gtr:id><gtr:impact>This collaboration began in March 2016 and we have held one preliminary meeting with partners. Bruce Alexander visited my group on 9th March 2016 and we have finalised a plan for research activities.</gtr:impact><gtr:outcomeId>56e03800b20f91.67869000-1</gtr:outcomeId><gtr:partnerContribution>Expertise in product development and design ideas</gtr:partnerContribution><gtr:piContribution>Expertise in vector behaviour and molecular xenomonitoring</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Blueberry Therapeutics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC_CiC_CRro_nanoP</gtr:description><gtr:id>1116F606-821B-4871-A27C-917B3B806B65</gtr:id><gtr:impact>Research still in progress, but as of February 2017 is nearing completion. Stable model of macrophage infection by S. Typhi created and observed on high throughput imaging platforms. Experimental infection and treatment of cell lines now complete and data being analysed.</gtr:impact><gtr:outcomeId>56e03529ceb446.30557962-1</gtr:outcomeId><gtr:partnerContribution>Coformuations of ceftriaxone with nanopolymer - this work is now complete</gtr:partnerContribution><gtr:piContribution>The phase based at LSTM commenced on 1st April 2016. We have developed a model for evaluating the intracellular compartment during Salmonella Typhi infection and are currently completing experiments using ceftriaxone/nanopolymer combinations. This work is on course to finish on time at the end of Septmeber 2016.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Avacta Group</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Avacta</gtr:description><gtr:id>CD64AF0D-84A0-4DE0-9AFF-64F0CA3E7CF9</gtr:id><gtr:impact>Confidentiality agreement</gtr:impact><gtr:outcomeId>57dbb62589fe62.08390005-1</gtr:outcomeId><gtr:partnerContribution>Avacta are preparing MOU and in IP nergotiations to prepare the ground for funding of a venom reserach project</gtr:partnerContribution><gtr:piContribution>Contacts made following Adhiron CiC project and meeting held in Leeds for networking Adhiron technology. Avacta have interests in venoms,thus connections made with Dr Harrison and Venom Research Unit to develop reserach project</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vaccitech Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration to accelerate development of vaccines against MERS-CoV</gtr:description><gtr:id>E78BCCA1-BC9C-4321-BD00-0D305D37AB5B</gtr:id><gtr:impact>A single dose of the vaccine administered intramuscularly or intranasally has been shown to provide 100% efficacy against lethal challenge in mice. Analysis of antibody titres, viral titres and histopathology are currently underway. 

Dromedary camels are now being recruited into the study at IRED, Chad and vaccine and consumable shipment will soon commence. We expect to immunise in December 2016, with results expected as from January 2017.</gtr:impact><gtr:outcomeId>57d255b360b593.98207919-3</gtr:outcomeId><gtr:partnerContribution>Vincent Munster's group at NIAID's Rocky Mountain Laboratories is testing the efficacy of the vaccine using his established transgenic mouse model.

IRED in Chad is providing camel immunisation and immunogenicity assessment. 

Vaccitech Limited, a recent University of Oxford spin-out with exclusive rights to our MERS vaccine, has provided co-funding to support camel challenge studies in Morocco.

We have sent vaccine to both these institutions, and they will send back results from mutually agreed study designs.</gtr:partnerContribution><gtr:piContribution>My research team has contributed a leading rationally designed vaccine candidate, that has already shown promise in preliminary immunogenicity studies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Clatterbridge Cancer Centre NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Neutrophil bead assay: Paediatric validation</gtr:description><gtr:id>AD8CC78B-F33C-4B48-A83D-37CB577D40FA</gtr:id><gtr:impact>No output yet</gtr:impact><gtr:outcomeId>56de83302b14a0.89710156-2</gtr:outcomeId><gtr:partnerContribution>Alder Hey: Development of paediatric protocol, and submission of REC application. Commitment of nursing support to consent and obtain blood samples
Clatterbridge: Collaborative development of a sampling strategy to identify patients with haematological malignancies receiving initial immunosuppressive treatment. This will be developed into an application for further funds to enable cross-sectional sampling of high risk patients in which the utility of the assay can be assessed</gtr:partnerContribution><gtr:piContribution>Alder Hey: Two senior investigators have partnered with us to provide access to samples from septic children in order to extend the usefulness of the assay into this age group
Clatterbridge: Commitment from oncologist to assessing the potential of this assay for identifying patients at risk of neutropenic sepsis</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vellore Institute of Technology (VIT) University</gtr:collaboratingOrganisation><gtr:country>India, Republic of</gtr:country><gtr:description>VIT</gtr:description><gtr:id>D621C5D2-4794-47B0-B747-DF3ABBFE2C6E</gtr:id><gtr:impact>Adjunct Professorship (M Paine)
MOU
High level meeting (Nov 2015) for Institutional teaching partnership
Multidisciuplinary collaboraton - Research/ educational</gtr:impact><gtr:outcomeId>57dbbd71c94b70.82339118-1</gtr:outcomeId><gtr:partnerContribution>Awarded Adjunct Professorship to M Paine. Progressed instututional agreements.</gtr:partnerContribution><gtr:piContribution>Research presentation and visit to VIT in 2014, leading to research and teaching links with Dept of Nanobiotechnology. Made links between LSTM International Education and Knowledge Exchange Initiatives (Michael Lurie) and VIT Director, International Relations for institutional cooperation and student exchange</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Instituto Butantan</gtr:collaboratingOrganisation><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:description>Collaboration with Butantan</gtr:description><gtr:id>EE564CFF-C41A-4897-923F-F35A97EBDB9E</gtr:id><gtr:impact>Development of molecular assays in progress.</gtr:impact><gtr:outcomeId>56deb36229d0b4.86564935-1</gtr:outcomeId><gtr:partnerContribution>Development of dengue, chikungunya and zika molecular assays</gtr:partnerContribution><gtr:piContribution>We established collaborative links with the reference surveillance centres for the State of Sergipe and with Butantan Institute (Sao Paulo, Brazil) for the development of dengue, chikungunya and zika molecular assays</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Epistem</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Epistem</gtr:description><gtr:id>ED4F6EFD-AA4C-4B1D-AA07-4CC048A1AAFB</gtr:id><gtr:impact>Diagnostic probes for kdr resistance, pilot data for proof of principle use of probes with Genedrive technology.</gtr:impact><gtr:outcomeId>57db25ac9a6647.91295782-1</gtr:outcomeId><gtr:partnerContribution>Production of probes for Genedrive system</gtr:partnerContribution><gtr:piContribution>Development of diagnostic probes for kdr resistance in An. gambiae</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>MRC CiC PDE project Pfizer</gtr:description><gtr:id>405AF590-EC8E-4355-9698-059B0DFEB82A</gtr:id><gtr:impact>No outputs as yet</gtr:impact><gtr:outcomeId>56dd8041c2d798.83941745-1</gtr:outcomeId><gtr:partnerContribution>Provision of compounds (still awaiting delivery)</gtr:partnerContribution><gtr:piContribution>Screening PDE inhibitors for activity against malaria parasites</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Alder Hey Children's NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Neutrophil bead assay: Paediatric validation</gtr:description><gtr:id>66212762-2015-4884-8FF6-5B5DCCBDA48F</gtr:id><gtr:impact>No output yet</gtr:impact><gtr:outcomeId>56de83302b14a0.89710156-1</gtr:outcomeId><gtr:partnerContribution>Alder Hey: Development of paediatric protocol, and submission of REC application. Commitment of nursing support to consent and obtain blood samples
Clatterbridge: Collaborative development of a sampling strategy to identify patients with haematological malignancies receiving initial immunosuppressive treatment. This will be developed into an application for further funds to enable cross-sectional sampling of high risk patients in which the utility of the assay can be assessed</gtr:partnerContribution><gtr:piContribution>Alder Hey: Two senior investigators have partnered with us to provide access to samples from septic children in order to extend the usefulness of the assay into this age group
Clatterbridge: Commitment from oncologist to assessing the potential of this assay for identifying patients at risk of neutropenic sepsis</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Keystone Symposia conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C3EB7323-D805-48C5-96A8-6D75CAAA7D12</gtr:id><gtr:impact>The meeting was focused on One Health and had talks on veterinary and human vaccinology. I was invited to give a talk on the use of viral vectors for co-development of vaccines that can be used in both humans and animals. MERS is an excellent example of one such disease indication.</gtr:impact><gtr:outcomeId>5837e1c2be8549.00553599</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Speaker at 1st International Congress of Vector-Borne Diseases.  10-11 Sep 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5F3F9EA3-E860-4965-A00E-F12B0F2A1E15</gtr:id><gtr:impact>I was invited to deliver a lecture on Vector-Borne diseases and discuss the research and progress of my group, focusing on vaccine development. Conference was in Zamora, Michoacan, Mexico. More than 500 attendees including the ministry of Health of Mexico and Michoacana, as well as postgraduate students and practitioners.</gtr:impact><gtr:outcomeId>57e9473c383325.64230512</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Speaker at the &quot;Closing the Global Health Divide through Partnership Driven Innovation Meeting&quot;</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CBD82EA0-DC0D-44E5-9FE4-C842B1117CEE</gtr:id><gtr:impact>The event represented a collective call for greater cross-border and cross-sector collaboration to ensure global preparedness for the inevitable resurgence of infectious diseases that disproportionally affect the poorest of the poor in developing countries. A series of presentations and interactive panels articulated the need for partnerships in global health and explored the challenges associated with R&amp;amp;D for infectious diseases.</gtr:impact><gtr:outcomeId>56b217b99adc11.71209681</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at MRC CiC NTD consortium meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BAA6CD33-9BED-4C15-A99E-3EA8B3C29324</gtr:id><gtr:impact>I gave a presentation on the results of the project of which the MRC CiC was granted for us to complete. In attendance were other grant holders in both academia and industry. Also potential applicants who were actively seeking funding were able to see some of the results and progress of a existing project.</gtr:impact><gtr:outcomeId>58b6f023af2a45.63609109</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Kensington and Chelsea Science Festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7A7ABC88-46EB-4149-B686-88435FFC30AF</gtr:id><gtr:impact>17th Oct 2015, Kensington and Chelsea Science Festival, Kensington Town Hall, London. &amp;quot;Tropical diseases: new solutions for tackling old problems&amp;quot;: the talk wqas to a braod audience of ~30/40 people, including Major of Kensington/ Chelsea, school children, public and councillors. The talk provoked discussion about the use of insecticides in disase control.</gtr:impact><gtr:outcomeId>56dd59f0058020.44099962</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.youtube.com/watch?v=dlDmTngEW7w&amp;feature=share</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1866981</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UK Vaccine Network</gtr:description><gtr:end>2019-08-02</gtr:end><gtr:fundingOrg>Department of Health Social Services and Public Safety (DHSSPS)</gtr:fundingOrg><gtr:fundingRef>R45331/CN001</gtr:fundingRef><gtr:id>69DCE9C9-1578-4EA5-804B-FC69DCB71A26</gtr:id><gtr:outcomeId>57d259d3425dd0.48555130</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>46750</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confidence in Concept (CiC) by MRC</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>00CE33D9-69FB-405D-8F65-3D0D8060C041</gtr:id><gtr:outcomeId>5692b329113ff4.06267622</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Confidence in Concept Scheme</gtr:department><gtr:description>MRC</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C37A252F-14D1-4FB1-879A-A15A5EABB778</gtr:id><gtr:outcomeId>58ca68f765b1e5.26321995</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Studentship</gtr:description><gtr:end>2019-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D07DBA5B-C143-4A8D-B79F-1FBC991618A4</gtr:id><gtr:outcomeId>56db0d555bd236.37579689</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Zika Rapid Response</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>ZK/16-025</gtr:fundingRef><gtr:id>111C0D16-73CD-415B-81E7-AFC03BD797EC</gtr:id><gtr:outcomeId>56e2802ad5ae08.46930240</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>502000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Global Challenges Research Fund</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C5FD0B85-B222-4CB3-B08E-A833AEDE475E</gtr:id><gtr:outcomeId>58985ceb9ae510.39108882</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>141916</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Grand Challenge Explorations Phase II</gtr:description><gtr:end>2019-02-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>3E29145D-1C42-444E-9F7D-AC3803679331</gtr:id><gtr:outcomeId>58985c9751d509.43142010</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Co-funding from Industry</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Vaccitech Ltd</gtr:fundingOrg><gtr:id>0985A6E1-8D06-4789-8D0C-23FFCAFC8BE2</gtr:id><gtr:outcomeId>583829ab4c6f25.24795417</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>? UK management committee member for COST Action CM1307, 'Targeted chemotherapy towards diseases caused by endoparasites&amp;quot; - 2014- to date</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>B55771A9-9E90-405C-8203-A76E1F779E20</gtr:id><gtr:outcomeId>56ddaeb04727c0.83647859</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.costcm1307.org/CM1307/Home.html</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Membership of the Structure-guided Drug Discovery Coalition</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>F10AAF76-261C-4126-A7E3-66374A173641</gtr:id><gtr:outcomeId>56b21c993e2727.06201923</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the MMV External Scientific Advisory Board 2017 to date</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>8A8B1FD5-F1DA-4186-8EBD-AE1D70D6770C</gtr:id><gtr:outcomeId>58c7ce99550d66.70277946</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>External advice to major funder with regard to antimalarial drug discovery projects</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>7C4EA2BD-D39E-48D4-A2FC-B91BCD282B00</gtr:id><gtr:outcomeId>58221de4d4eb66.30605490</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Macrofilaricide Drug Accelerator (MacDA)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>271C755C-A82B-4059-9104-5479F7AA37B8</gtr:id><gtr:outcomeId>56c5baf6710884.05438375</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>External Scientific Advisory Board Member for the German Centre for Infection Research</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>62310FA0-BABE-4DC7-A077-E9561454E4EA</gtr:id><gtr:outcomeId>56b21dad3e2558.73697929</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Background

The search for highly effective anti-malarial therapies has gathered pace and recent years have seen a number of promising single and combined therapies reach the late stages of development. A key drug development challenge is the need for early assessment of the clinical utility of new drug leads as it is often unclear for developers whether efforts should be focused on efficacy or metabolic stability/exposure or indeed whether the continuation of iterative QSAR (quantitative structure-activity and relationships) cycles of medicinal chemistry and biological testing will translate to improved clinical efficacy. Pharmacokinetic and pharmacodynamic (PK/PD)-based measurements available from in vitro studies can be used for such clinical predictions. However, these predictions often require bespoke mathematical PK/PD modelling expertise and are normally performed after candidate development and, therefore, not during the pre-clinical development phase when such decisions need to be made.

Methods

An internet-based tool has been developed using STELLA&amp;reg; software. The tool simulates multiple differential equations that describe anti-malarial PK/PD relationships where the user can easily input PK/PD parameters. The tool utilizes a simple stop-light system to indicate the efficacy of each combination of parameters. This tool, called OptiMal-PK, additionally allows for the investigation of the effect of drug combinations with known or custom compounds.

Results

The results of simulations obtained from OptiMal-PK were compared to a previously published and validated mathematical model on which this tool is based. The tool has also been used to simulate the PK/PD relationship for a number of existing anti-malarial drugs in single or combined treatment. Simulations were predictive of the published clinical parasitological clearance activities for these existing therapies.

Conclusions

OptiMal-PK is designed to be implemented by medicinal chemists and pharmacologists during the pre-clinical anti-malarial drug development phase to explore the impact of different PK/PD parameters upon the predicted clinical activity of any new compound. It can help investigators to identify which pharmacological features of a compound are most important to the clinical performance of a new chemical entity and how partner drugs could potentially improve the activity of existing therapies.</gtr:description><gtr:id>D1245684-2084-4037-AA36-FF8A868502E7</gtr:id><gtr:impact>The software has been used by a number of users for both teaching and research purposes. The use of the model has lowered the number of animal experiments in my laboratory but it is difficult to estimate how many in vivo experiments it has reduced externally. We are currently working to promote the on-line tool.</gtr:impact><gtr:outcomeId>58c6983c6c13b7.44669497</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens</gtr:title><gtr:type>Computer model/algorithm</gtr:type><gtr:url>http://optimalpk.lstmed.ac.uk</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>We have conducted prospective evaluations of novel RT-PCR assays for the diagnosis of dengue and chikungunya in Ecuador, Guatemala and Brazil. The new assays were compared to the reference standard in the national surveillance laboratories (the CDC assays for these viruses).</gtr:description><gtr:id>8D60FF96-2D5B-41A3-A697-FC553E316A60</gtr:id><gtr:impact>We are currently conducting sequencing of selected samples to confirm our findings. Pending final confirmation, the assays developed (by LSTM in collaboration with Qiagen) are as sensitive and specific as the reference standard</gtr:impact><gtr:outcomeId>56deb79cbea1b3.69712260</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>prospective evaluations of novel RT-PCR assays for the diagnosis of dengue and chikungunya</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Probes for detecting resistance mutations in pyrethroid target (kdr)</gtr:description><gtr:id>00138A30-F59D-494E-96FB-52634A22505F</gtr:id><gtr:impact>Still being validated</gtr:impact><gtr:outcomeId>57db277fecc942.30338680</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Genedrive kdr probes</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8D4914FB-C289-4A75-B3B8-6FE0E55421CD</gtr:id><gtr:title>Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model.</gtr:title><gtr:parentPublicationTitle>NPJ vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/532d2c9a201f6ae24b218d944b2d98d0"><gtr:id>532d2c9a201f6ae24b218d944b2d98d0</gtr:id><gtr:otherNames>Munster VJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2059-0105</gtr:issn><gtr:outcomeId>5aa783f38cb8f8.48323609</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>400FA043-BCE4-4C60-8E09-4951ABE559FA</gtr:id><gtr:title>Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV+ Population Is Not Related to Antiretroviral Therapy.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01e4ebb681ccf6798567dcd0ff136045"><gtr:id>01e4ebb681ccf6798567dcd0ff136045</gtr:id><gtr:otherNames>T?r?k ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>58c7cda7b071f0.39970043</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22068E9E-053A-4B9D-A6A4-BCCF2E704038</gtr:id><gtr:title>Corrigendum: A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4212d48fb2be0f6cd4cdc97f750f256b"><gtr:id>4212d48fb2be0f6cd4cdc97f750f256b</gtr:id><gtr:otherNames>Ismail HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>58c7cda72f7a50.40072733</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B555D5D7-8BA0-4777-8F60-F387111C9930</gtr:id><gtr:title>A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4212d48fb2be0f6cd4cdc97f750f256b"><gtr:id>4212d48fb2be0f6cd4cdc97f750f256b</gtr:id><gtr:otherNames>Ismail HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0044-8249</gtr:issn><gtr:outcomeId>582445d92037f5.81178827</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18F6633C-0727-4433-8AD2-A92C90FD1E05</gtr:id><gtr:title>ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9dbac0664cc171b38fab6d7e3d675e7a"><gtr:id>9dbac0664cc171b38fab6d7e3d675e7a</gtr:id><gtr:otherNames>Alharbi NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5aa783f3be20f2.25498757</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4612FA5A-AFF4-40B6-9DD6-C2C3385283B5</gtr:id><gtr:title>Carbamoyl Triazoles, Known Serine Protease Inhibitors, Are a Potent New Class of Antimalarials.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5211771b9988c81aea61d371b9ad55e4"><gtr:id>5211771b9988c81aea61d371b9ad55e4</gtr:id><gtr:otherNames>McConville M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>56b1f1003b46c4.21082368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB71F0F1-AC87-4912-90B1-07BEAA2EEE73</gtr:id><gtr:title>Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4212d48fb2be0f6cd4cdc97f750f256b"><gtr:id>4212d48fb2be0f6cd4cdc97f750f256b</gtr:id><gtr:otherNames>Ismail HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>582219d0dc3c80.24009746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D60AD34-8C5D-4776-9DAD-DE5223B7B624</gtr:id><gtr:title>A validated bioluminescence-based assay for the rapid determination of the initial rate of kill for discovery antimalarials.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cfc0d6f124198059af525f598f094aa"><gtr:id>2cfc0d6f124198059af525f598f094aa</gtr:id><gtr:otherNames>Ullah I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>58c67a9bc89b21.81770930</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0C7EFAA-6A20-49D1-8411-AB6FF9ABFB55</gtr:id><gtr:title>Influence of theGene on In Vitro Sensitivities of Piperaquine in Thai Isolates of.</gtr:title><gtr:parentPublicationTitle>The American journal of tropical medicine and hygiene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/690909a391a0c1aab3ba74b8b327a637"><gtr:id>690909a391a0c1aab3ba74b8b327a637</gtr:id><gtr:otherNames>Mungthin M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-9637</gtr:issn><gtr:outcomeId>58c7cda78786e3.48202906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FA5D3DC-5167-4F9F-9FF0-40ED5CD83AE3</gtr:id><gtr:title>OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e3511efcc710829c2226c3891942d74"><gtr:id>1e3511efcc710829c2226c3891942d74</gtr:id><gtr:otherNames>Aljayyoussi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>585d3caeb0c0b3.96990550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DC229C5-E72C-48F9-80C5-A0C8145720F0</gtr:id><gtr:title>A simple breath test for tuberculosis using ion mobility: A pilot study.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88ce30a76d276e0ea052acc81bb19e3f"><gtr:id>88ce30a76d276e0ea052acc81bb19e3f</gtr:id><gtr:otherNames>Sahota AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>585d6b1c51b609.97404561</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F700351B-9176-4143-BDF5-43B289DD76E2</gtr:id><gtr:title>PFMDR1 POLYMORPHISMS INFLUENCE ON IN VITRO SENSITIVITY OF THAI PLASMODIUM FALCIPARUM ISOLATES TO PRIMAQUINE, SITAMAQUINE AND TAFENOQUINE.</gtr:title><gtr:parentPublicationTitle>The Southeast Asian journal of tropical medicine and public health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6059000f7b5ed7c42535268802fac5a8"><gtr:id>6059000f7b5ed7c42535268802fac5a8</gtr:id><gtr:otherNames>Kaewpruk N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0125-1562</gtr:issn><gtr:outcomeId>582219d13bdb22.09954819</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E67A052-02B6-4A0B-BB14-1A3281B3C8A1</gtr:id><gtr:title>Analytical and clinical performance of a Chikungunya qRT-PCR for Central and South America.</gtr:title><gtr:parentPublicationTitle>Diagnostic microbiology and infectious disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45e39a0a2ca997212fee6634c32644e5"><gtr:id>45e39a0a2ca997212fee6634c32644e5</gtr:id><gtr:otherNames>Edwards T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0732-8893</gtr:issn><gtr:outcomeId>5aaa85fc9412b4.38038612</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CC31A05-7EDC-45A0-A6D8-544D66C164DD</gtr:id><gtr:title>Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e3511efcc710829c2226c3891942d74"><gtr:id>1e3511efcc710829c2226c3891942d74</gtr:id><gtr:otherNames>Aljayyoussi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a361b24d8a8a6.08441118</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8642DB9-3682-4384-BED5-11144FBD06A6</gtr:id><gtr:title>2-Pyridylquinolone
 antimalarials with improved antimalarial activity and physicochemical properties</gtr:title><gtr:parentPublicationTitle>MedChemComm</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8b7d9a6884c2f596793e573ed8cbe50"><gtr:id>d8b7d9a6884c2f596793e573ed8cbe50</gtr:id><gtr:otherNames>Charoensutthivarakul S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2040-2503</gtr:issn><gtr:outcomeId>56b1f1a3c08cb4.35220632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC5CBE12-0DD1-465D-95EC-FD97D8C9C2F0</gtr:id><gtr:title>A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4212d48fb2be0f6cd4cdc97f750f256b"><gtr:id>4212d48fb2be0f6cd4cdc97f750f256b</gtr:id><gtr:otherNames>Ismail HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>582445d8e08c69.72871232</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7963A438-C7A6-4FE5-B3B9-3C2515F34D31</gtr:id><gtr:title>A Quinoline Carboxamide Antimalarial Drug Candidate Uniquely Targets Plasmodia at Three Stages of the Parasite Life Cycle.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a06c05b3620f7d7cdab1f4b38cdaeaef"><gtr:id>a06c05b3620f7d7cdab1f4b38cdaeaef</gtr:id><gtr:otherNames>O'Neill PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>56b1f123e36193.28350084</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_14111</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>